12:00 AM
 | 
Sep 01, 2008
 |  BioCentury  |  Product Development

Blockbuster bombing

Targanta Therapeutics Corp. is expected to release top-line Phase II data on Tuesday that would show its oritavancin could work as a single infusion to treat complicated skin and skin structure infections caused by Gram-positive pathogens. This would be a huge advantage over the competition, which requires once- or twice-daily infusions over 7-14 days.

President and CEO Mark Leuchtenberger told BioCentury that 70-75% of patients with Gram-positive cSSSIs are treated with vancomycin, which is given in 1-hour infusions twice daily for 10-14 days.

Even Cubicin daptomycin from Cubist Pharmaceuticals Inc., a newer cSSSI treatment, is given in once-daily infusions for 7-14 days.

“This is a tremendous burden on patients, doctors and the healthcare system,” Leuchtenberger said. “A single infusion of 90 minutes to 2.5 hours would save the healthcare system lots of time and money, while improving quality and delivery of care.”

CSO Tom Parr had the idea for giving oritavancin in a single large bolus based on work he did...

Read the full 800 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >